# Samsung Bioepis Co., Ltd. clinical trials: 33 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 33 trials with Samsung Bioepis Co., Ltd. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Samsung Bioepis Co., Ltd.: 33 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/samsung-bioepis-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 33
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 33, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 28, 2026 | NCT07844343 | A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic... | Samsung Bioepis Co., Ltd. | Phase 2 | Completed | Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO, Diabetic Macular Oedema | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844343) |
| August 27, 2026 | NCT07789964 | A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in... | Samsung Bioepis Co., Ltd. | Phase 1 | Recruiting | Healthy | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789964) |
| April 24, 2026 | NCT07550504 | A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV | Samsung Bioepis Co., Ltd. | Phase 2 | Completed | Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550504) |
| April 13, 2026 | NCT07524348 | A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors | Samsung Bioepis Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumors | 149 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524348) |
| April 4, 2024 | NCT06348199 | A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic... | Samsung Bioepis Co., Ltd. | Phase 3 | Active not recruiting | Non-small Cell Lung Cancer Stage IV | 555 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06348199) |
| February 20, 2024 | NCT06268613 | A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced... | Samsung Bioepis Co., Ltd. | Phase 1 | Active not recruiting | Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA | 163 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06268613) |
| December 20, 2023 | NCT06176963 | A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO | Samsung Bioepis Co., Ltd. | Phase 2 | Completed | Neovascular Age-related Macular Degeneration, Macular Edema, Retinal Vein Occlusion | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06176963) |
| August 22, 2022 | NCT05510063 | Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis | Samsung Bioepis Co., Ltd. | Phase 4 | Completed | Plaque Psoriasis | 371 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05510063) |
| July 19, 2021 | NCT04967508 | A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis | Samsung Bioepis Co., Ltd. | Phase 3 | Completed | Psoriasis, Moderate to Severe Plaque Psoriasis | 503 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04967508) |
| February 26, 2021 | NCT04772274 | A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced... | Samsung Bioepis Co., Ltd. | Phase 1 | Completed | Healthy | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04772274) |
| December 11, 2020 | NCT04664959 | A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis | Samsung Bioepis Co., Ltd. | Phase 3 | Completed | Postmenopausal Osteoporosis | 457 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04664959) |
| November 9, 2020 | NCT04621318 | Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects | Samsung Bioepis Co., Ltd. | Phase 1 | Completed | Healthy | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04621318) |
| August 17, 2020 | NCT04514796 | Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects | Samsung Bioepis Co., Ltd. | Phase 1 | Completed | Healthy | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04514796) |
| June 29, 2020 | NCT04450329 | A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD) | Samsung Bioepis Co., Ltd. | Phase 3 | Completed | Neovascular Age-related Macular Degeneration | 449 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04450329) |
| August 15, 2019 | NCT04058158 | A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria | Samsung Bioepis Co., Ltd. | Phase 3 | Completed | Paroxysmal Nocturnal Hemoglobinuria | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04058158) |
| October 26, 2018 | NCT03722329 | Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects | Samsung Bioepis Co., Ltd. | Phase 1 | Completed | Healthy | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03722329) |
| August 15, 2018 | NCT03630627 | A Phase I Study of SB26 in Healthy Volunteers | Samsung Bioepis Co., Ltd. | Phase 1 | Completed | Healthy Volunteers | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03630627) |
| June 21, 2017 | NCT03193957 | An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With... | Samsung Bioepis Co., Ltd. | Phase 2 | Completed | Rheumatoid Arthritis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03193957) |
| June 20, 2017 | NCT03193203 | Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects | Samsung Bioepis Co., Ltd. | Phase 1 | Completed | Healthy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03193203) |
| May 12, 2017 | NCT03150589 | A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) | Samsung Bioepis Co., Ltd. | Phase 3 | Completed | Age-Related Macular Degeneration | 705 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03150589) |
| May 13, 2016 | NCT02771795 | A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC | Samsung Bioepis Co., Ltd. | Observational | Terminated | Breast Neoplasms | 538 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02771795) |
| April 28, 2016 | NCT02754882 | A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | Samsung Bioepis Co., Ltd. | Phase 3 | Completed | Lung Cancer, Non-small Cell Lung Cancer | 763 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02754882) |
| October 1, 2015 | NCT02565810 | An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With... | Samsung Bioepis Co., Ltd. | Phase 2 | Completed | Rheumatoid Arthritis | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02565810) |
| May 25, 2015 | NCT02453672 | Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects | Samsung Bioepis Co., Ltd. | Phase 1 | Completed | Healthy | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02453672) |
| December 29, 2014 | NCT02326233 | Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects | Samsung Bioepis Co., Ltd. | Phase 1 | Completed | Healthy | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02326233) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 2 | 5 |
| Phase 3 | 11 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 28 |
| Recruiting | 2 |
| Active not recruiting | 2 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Arthritis, Rheumatoid | 5 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Psoriasis | 2 |
| Macular Degeneration | 2 |
| Osteoporosis, Postmenopausal | 1 |
| Macular Edema | 1 |
| Retinal Vein Occlusion | 1 |
| Lung Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Neoplasms | 1 |
| Hemoglobinuria, Paroxysmal | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Mediterranean restaurants in the United States](https://specstream.ai/data/businesses/mediterranean-restaurants/united-states)
- [Test preparation centers in the United States](https://specstream.ai/data/businesses/test-preparation-centers/united-states)
- [Carpet cleaning companies in the United States](https://specstream.ai/data/businesses/carpet-cleaning-companies/united-states)
- [Hotels in the United States](https://specstream.ai/data/businesses/hotels/united-states)
- [Publishers in the United States](https://specstream.ai/data/businesses/publishers/united-states)
- [Automation companies in the United States](https://specstream.ai/data/businesses/automation-companies/united-states)
